Skip to Content

TerrAscend Corp TSND

Morningstar Rating
CAD 1.85 +0.04 (2.21%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

TSND is trading at a 615% premium.
Price
CAD 1.82
Fair Value
CAD 9.51
Uncertainty
Very High
1-Star Price
CAD 6.73
5-Star Price
CAD 9.94
Economic Moat
Nzj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TSND is a good fit for your portfolio.

News

Trading Information

Previous Close Price
CAD 1.81
Day Range
CAD 1.791.96
52-Week Range
CAD 1.723.21
Bid/Ask
CAD 1.84 / CAD 1.85
Market Cap
CAD 542.20 Mil
Volume/Avg
75,999 / 271,043

Key Statistics

Price/Earnings (Normalized)
9.64
Price/Sales
1.16
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

TerrAscend Corp is a company focused on creating and delivering quality cannabis products and services that meet the evolving needs of its patients. It also provides education and support programs to physicians and patients through healthcare professionals. It has one operating segment, being cultivation, production, and sale of cannabis products, with subsidiaries located in Canada and the United States.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
36

Comparables

Valuation

Metric
TSND
AGL
NBLY
Price/Earnings (Normalized)
9.6437.89
Price/Book Value
1.694.111.42
Price/Sales
1.160.590.95
Price/Cash Flow
71.9313.98
Price/Earnings
TSND
AGL
NBLY

Financial Strength

Metric
TSND
AGL
NBLY
Quick Ratio
0.211.300.40
Current Ratio
0.491.331.14
Interest Coverage
−0.59−31.07−0.27
Quick Ratio
TSND
AGL
NBLY

Profitability

Metric
TSND
AGL
NBLY
Return on Assets (Normalized)
−4.95%−6.93%−1.59%
Return on Equity (Normalized)
−12.78%−17.98%−2.93%
Return on Invested Capital (Normalized)
−2.45%−16.40%0.86%
Return on Assets
TSND
AGL
NBLY
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
WndvmfqqbNshymdd$81.0 Bil
Zoetis Inc Class A
ZTS
GhcpyrzhDwfhp$78.2 Bil
Haleon PLC ADR
HLN
XqfcyftZhdc$38.1 Bil
Teva Pharmaceutical Industries Ltd ADR
TEVA
QkzhqxxhRftl$19.6 Bil
Viatris Inc
VTRS
LkblvgdsRdrr$12.4 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
QbmhnpqsHygxd$12.2 Bil
Catalent Inc
CTLT
NxgzlpqkJjqvmt$10.1 Bil
Perrigo Co PLC
PRGO
XfbspkpfxPcg$3.7 Bil
Prestige Consumer Healthcare Inc
PBH
GcsfdsnnRnkgq$3.2 Bil
Curaleaf Holdings Inc
CURLF
DzjdkbvMsmf$3.2 Bil

Sponsor Center